Merus and Halozyme Sign Global Agreement to Develop Subcutaneous Version of Petosemtamab
Tuesday, November 18, 2025
Merus N.V., an oncology company focused on multispecific antibodies and antibody-drug conjugates, has entered into a global, non-exclusive collaboration and licence agreement with Halozyme Therapeutics, a specialist in subcutaneous drug delivery. Through this agreement, Merus will use Halozyme’s ENHANZE® drug delivery technology to develop and potentially commercialise a subcutaneous formulation of petosemtamab, an EGFR x LGR5 bispecific antibody.
Petosemtamab has shown promising activity in clinical studies for several solid tumours, including head and neck cancer. The collaboration aims to support the development of a subcutaneous version that may offer greater convenience and improved treatment experience for patients.
Under the agreement, Merus will provide Halozyme with an upfront payment and may make additional milestone payments based on commercial progress and sales achievements, if the product is approved. Halozyme will also receive low-to-mid single-digit royalties on net sales of petosemtamab formulated with ENHANZE® during the royalty period.
Source: prnewswire.com
